• KAFM
  • Contact us
  • E-Submission
ABOUT
ARTICLE CATEGORY
BROWSE ARTICLES
AUTHOR INFORMATION

Articles

Review Article

Smoking cessation policy gaps in South Korea: an MPOWER Framework analysis with AI-assisted multi-source evidence synthesis (2021–2026)

Published online: October 1, 2026

1Department of Occupational and Environmental Medicine, Dankook University Hospital, Cheonan, Korea

2Mobile Doctor Inc., Seoul, Korea

3MoDoc AI Inc., Needham, MA, USA

4Department of Family Medicine, Dankook University Hospital, Cheonan, Korea

*Corresponding Author: Yoo-Seock Cheong Tel: +82-41-550-6385, Fax: +82-41-556-0524, E-mail: drloved@hanmail.net
*Current affiliation: The author (Sang Hyun Ahn) is now with the Department of Family Medicine, Dankook University Hospital, Cheonan, Korea.
• Received: March 20, 2026   • Revised: June 17, 2026   • Accepted: June 18, 2026

© 2026 The Korean Academy of Family Medicine

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 806 Views
  • 24 Download
  • Smoking remains the leading preventable cause of death in South Korea, accounting for 58,000–68,000 deaths annually and socioeconomic costs of approximately ₩15 trillion. Despite demonstrated cessation program effectiveness, participation has declined 62% since 2017, and Korea’s tobacco landscape is undergoing rapid transformation—including a decade-long cigarette price freeze, one of the world’s highest heated tobacco product market shares (18.4%), and the widening gap between total tobacco product use and cigarette-only prevalence. This review applies the World Health Organization Framework Convention on Tobacco Control MPOWER framework to identify policy gaps and strategic priorities for Korean smoking cessation during 2021–2026. We synthesized evidence from PubMed, Cochrane Library, Embase, KoreaMed, and RISS, supplemented by an artificial intelligence-assisted multi-source corroboration protocol using four independent platforms with primary-source verification of all cited claims. Four strategic priorities emerge, ranked by anticipated population-level impact. First, price and packaging policy reform: the 10-year price freeze at ₩4,500 (fifth lowest among Organization for Economic Cooperation and Development countries) represents the most significant modifiable barrier, with expert consensus recommending ₩8,000–10,000 with inflation indexation. Second, evidence-based novel product regulation: marked divergence among international guidelines on e-cigarettes demands a calibrated Korean approach balancing adult cessation benefits against youth initiation risks. Third, product-specific monitoring: total tobacco product use should replace cigarette-only prevalence as the primary national indicator. Fourth, pharmacotherapy optimization and digital integration: combination nicotine replacement therapy showed no clear difference versus varenicline in network meta-analysis (odds ratio, 1.06; 95% credible interval, 0.75–1.48), and digital cessation interventions (relative risk, 1.86) warrant consideration for integration into Korean cessation services. The December 2025 Tobacco Business Act amendment creates a legislative window to address these gaps comprehensively.
Smoking remains the leading preventable cause of death in South Korea, accounting for approximately 58,000–68,000 deaths annually and socioeconomic costs of approximately ₩15 trillion (US$11 billion) [1,2]. Yet Korea’s tobacco control landscape presents a striking paradox: despite demonstrated cessation program effectiveness—pharmacotherapy achieves 26% cessation rates, 5–8-fold higher than unaided attempts, and further enhanced 1.8-fold by physician counseling—cessation treatment participation has declined 62% since 2017, from 408,097 enrollees to approximately 155,000 in 2022, a decline likely reflecting sequential disruptions, including generic entry-related reimbursement cuts (2018), coronavirus disease 2019 (COVID-19)-related public health service contraction (2020–2021), and the varenicline impurity crisis that halted originator supply from September 2021, while the overall cessation budget has stagnated at approximately ₩90 billion [3].
Simultaneously, Korea’s tobacco product landscape is undergoing rapid transformation. Cigarette prices remained at ₩4,500 from 2015 through the review’s evidence cutoff [4]. Heated tobacco products (HTPs) have captured 18.4% of the domestic market—making Korea one of the world’s largest HTP markets—and the gap between total tobacco product use and cigarette-only prevalence is widening at an accelerating pace [4,5]. Among female adolescents, liquid e-cigarette use has surpassed cigarette use for the first time [6]. This evolving landscape demands a comprehensive reassessment of Korea’s smoking cessation strategy.
The World Health Organization (WHO) Framework Convention on Tobacco Control (FCTC) MPOWER framework provides a structured policy lens for identifying gaps relative to international evidence and best practices [7]. MPOWER’s six domains— monitor tobacco use, protect from tobacco smoke, offer help to quit, warn about dangers, enforce advertising bans, and raise taxes—provide a standardized framework for cross-national comparison and for prioritizing interventions by evidence strength and implementation feasibility.
The challenge of timely evidence synthesis is compounded by the sheer volume and complexity of emerging data. Generative artificial intelligence (AI) models have demonstrated substantial capacity for biomedical information retrieval and synthesis [8], but their application to scholarly evidence synthesis faces well-documented risks, including hallucination of fabricated citations, training data bias, and nondeterministic outputs [9,10]. Studies have reported AI hallucination rates of 5%–20% for biomedical references depending on the domain and model [11], and attempts to automate systematic review processes remain at an early stage [12]. Meanwhile, traditional systematic reviews average 67 weeks from registration to publication [13], creating a substantial lag between evidence generation and synthesis in rapidly evolving fields where policy windows are time-sensitive.
This review applies the MPOWER framework to synthesize clinical evidence and identify strategic priorities for Korean smoking cessation during 2021–2026, a period of unprecedented legislative change, evolving product landscapes, and persistent infrastructure gaps. Evidence was gathered through targeted database searches supplemented by an AI-assisted multi-source corroboration protocol using four independent generative AI platforms, with all claims verified against primary sources (detailed in Methods and Supplementary Materials).
MPOWER was selected over alternative analytical frameworks (the tobacco endgame framework, the Organization for Economic Cooperation and Development (OECD) Tobacco Control Scale, and FCTC article-by-article compliance audits) for three reasons: (1) ease of communication with policy gatekeepers and primary care clinicians, since MPOWER’s six domains map directly onto WHO best buys and are widely understood in the Korean public health and family medicine communities; (2) cross-national comparability, as MPOWER scores are routinely reported in WHO Reports on the Global Tobacco Epidemic; and (3) feasibility-oriented prioritization at the intervention domain level rather than at the level of individual treaty articles, which is appropriate for a policy-gap analysis intended to inform short-to-medium-term legislative action during the 2025–2026 reform window.
Reporting framework
This is a structured narrative policy review rather than a systematic or scoping review. Reporting was guided primarily by the Scale for the Assessment of Narrative Review Articles (SANRA; Baethge et al. [14] in 2019), a six-item, 12-point quality scale designed for non-systematic reviews. Search transparency was enhanced by adopting selected elements of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)-search extension for reporting literature searches (Rethlefsen et al. [15] in 2021), without claiming full PRISMA or PRISMA extension for scoping reviews compliance. The review was not prospectively registered; the search strategies, standardized prompts, and topic-mapping procedures described below, together with the Supplements 1–14 (SANRA application table, full Boolean search strings, representative AI prompts, evidence flow figure, and AI-use transparency table), are intended to provide a level of reproducibility appropriate for narrative reviews. Disclosure of generative-AI assistance follows the International Committee of Medical Journal Editors (ICMJE) 2024 and World Association of Medical Editors 2023 recommendations: AI tools were used to support evidence identification, source comparison, and discordance flagging, with all final inclusions, citations, numerical estimates, and policy interpretations verified by the human authors against primary sources.
Literature search strategy
We searched PubMed, Cochrane Library, Embase, KoreaMed, and RISS (Research Information Sharing Service, Korea) for literature published between 2021 and 2026, while foundational Cochrane systematic reviews, national reports, and guidelines were included regardless of publication year. Search terms covered pharmacotherapy (varenicline, bupropion, nicotine replacement therapy [NRT], cytisinicline), behavioral and digital interventions (Cognitive Behavioral Therapy, motivational interviewing, digital therapeutics, mHealth), novel nicotine products (e-cigarette, vaping, heated tobacco, IQOS, synthetic nicotine), and Korea-specific terms (Korea, tobacco, policy, epidemiology). Searches were conducted between January and February 2026 and last updated on February 28, 2026. During revision, we also conducted a documented, reproducible structured search using the Boolean strategies in Supplement 11 (search dates: May 15–17, 2026; evidence window: January 1, 2021, to May 17, 2026) to provide a transparent search record that complements the original narrative search. Inclusion criteria prioritized systematic reviews, meta-analyses, network meta-analyses, large randomized controlled trials (RCTs) (>100 participants), national-level surveys, and international and domestic guidelines. Studies with significant tobacco industry conflicts of interest were excluded, except when the scarcity of Korean data necessitated inclusion with explicit disclosure.
AI-assisted evidence synthesis
To enhance the efficiency and comprehensiveness of evidence retrieval, we employed a structured multi-source corroboration protocol using four independent generative AI platforms: Claude (Anthropic), ChatGPT (OpenAI), Gemini (Google), and Consensus (Consensus NLP). These platforms were selected to maximize diversity in training corpora and language coverage, which was particularly important for a topic requiring both English-language international evidence and Korean-language policy documents. Each platform received identical, standardized prompts covering the full scope of Korean smoking cessation topics. Outputs were organized into a nine-category topic-mapping matrix (Supplement 1), with each platform’s coverage coded and distinctive contributions documented (Supplement 2). All numerical values, dates, and factual claims were systematically cross-compared and verified against primary sources; 23 intersource discrepancies were identified, of which 78% were resolved through primary source verification (Supplement 3). The AI platforms served as tools for literature retrieval and preliminary synthesis under the direction of domain experts; all final content decisions, clinical interpretations, and policy recommendations represent the authors’ expert judgment. No AI tool is listed as an author, consistent with ICMJE recommendations. Full methodological details are provided in Supplements 1–4 [16].
We revised the terminology from “multi-model cross-validation" to “AI-assisted multi-source corroboration” to avoid confusion with statistical cross-validation procedures (e.g., k-fold or hold-out validation). In this review, the AI tools were not used to validate a predictive model; rather, outputs from three general-purpose large language models (Claude, Anthropic; ChatGPT, OpenAI; Gemini, Google) and one literature-indexed retrieval tool (Consensus, Consensus NLP) were compared with one another and verified against prespecified bibliographic databases, peer-reviewed articles, and official policy documents. Concordance across architecturally heterogeneous sources is used as a heuristic indicator of factual robustness, not as an assessment of statistical generalizability.
The standardized prompt protocol described above evolved iteratively during the synthesis period and was not preserved in verbatim form. Representative reconstructed prompts illustrating each request category are provided in Supplement 8 for transparency, with explicit acknowledgment that these are post hoc reconstructions rather than logged originals. AI tools were used to support evidence scoping, summarization, cross-source comparison, and discordance flagging; they were not used as independent validators, and all substantive claims were checked against primary or authoritative sources before inclusion.
Evidence assessment and organizational framework
Evidence quality was assessed using the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation; high, moderate, low, very low), prioritizing existing Cochrane GRADE assessments. Clinical results were organized according to the WHO FCTC MPOWER framework to facilitate alignment with international tobacco control standards and to highlight Korea-specific policy gaps. The MPOWER framework was used as an organizing lens for policy-gap analysis rather than as a domain-by-domain compliance audit [7].
Formal GRADE certainty assessment was applied only to pharmacotherapy intervention outcomes derived from Cochrane systematic reviews and randomized trials (Table 1). For policy-level outcomes—including price elasticity, plain packaging, harms associated with novel products, and digital cessation efficacy—we provide a narrative evidence summary in Supplement 13 without formal GRADE adjudication, given the heterogeneity of underlying study designs (econometric modeling, ecological analyses, cohort studies, randomized trials) and the absence of a prespecified outcome harmonization protocol typical of systematic reviews. Where existing systematic reviews have published GRADE certainty ratings for these outcomes, we extracted those ratings rather than generating new ones.
Monitor: smoking prevalence and the emerging surveillance gap
The 2023 Korea National Health and Nutrition Examination Survey reported current cigarette smoking prevalence rates of 32.4% among adult males and 6.3% among females—the first increases in 5 years [17]. Preliminary 2024 data showed returns to 28.5% (male) and 4.2% (female); this apparent fluctuation may reflect sampling variability rather than a true rebound, given that year-to-year fluctuations of ±2–4 percentage points are common in this dataset [5]. Female smoking rates may be substantially underestimated; cotinine-based studies have reported rates 2–3 times higher than those based on self-report (Table 2) [18].
A critical emerging metric is the widening gap between total tobacco product use and cigarette-only use. In 2024, total tobacco product use exceeded cigarette-only rates by 7.5 percentage points in males and 2.7 percentage points in females—gaps that widened from 6.5 and 2.0 percentage points, respectively, in 2023 [5]. This accelerating divergence indicates that cigarette-only prevalence no longer adequately captures the nation’s nicotine dependence burden. HTPs have captured 18.4% of the domestic market, making Korea one of the world’s largest HTP markets [4]. Among female adolescents, liquid e-cigarette use surpassed cigarette use for the first time, with 32% of adolescents who initiated smoking between 2019 and 2023 beginning with e-cigarettes [6].
The Youth Health Behavior Survey provides granular data on this transition: among adolescents who had ever smoked, the proportion initiating with e-cigarettes rather than combustible cigarettes has increased annually since 2019, with the sharpest rises among female students [6]. These data challenge the traditional surveillance paradigm, which assumes combustible cigarette initiation as the primary pathway to nicotine dependence. The implications for cessation policy are substantial: interventions designed for cigarette-dependent populations may be poorly calibrated for a generation whose nicotine exposure begins through alternative products.
Despite the documented mortality and economic burden noted in the Introduction [1,2], the contraction of cessation infrastructure described below is particularly concerning. Together, these findings expose a fundamental surveillance gap: Korea’s primary national indicator—current cigarette smoking rate—systematically underestimates total nicotine dependence in an era of product diversification.
Offer help: cessation services, pharmacotherapy, and digital integration
Korea’s cessation infrastructure operates through three complementary channels: the National Health Insurance Service (NHIS) cessation treatment program (8–12 weeks of pharmacotherapy-assisted treatment, with up to three cycles annually), community health center quit clinics, which reported a 33.3% 6-month success rate in 2024 [19], and regional cessation support centers delivering targeted outreach to underserved populations [3,20]. However, participation has declined dramatically—from 408,097 enrollees in 2017 to approximately 155,000 in 2022—with program completion rates stagnating at approximately 36% and only 14.7% of current smokers using any service [3]. Despite demonstrated effectiveness, the overall cessation budget has stagnated at approximately ₩90 billion [3].
The NHIS cessation treatment program, established in 2015, provides pharmacotherapy-assisted treatment covering varenicline, bupropion, and NRT with up to three cycles annually [21]. Despite this comprehensive design, program utilization data reveal a concerning trajectory: the program achieved peak enrollment of 408,097 in 2017 but has since declined steadily, with completion rates remaining below 40% even among enrollees [21]. This contraction is concerning given the established effectiveness of pharmacotherapy-assisted cessation programs, suggesting that declining use more likely reflects access barriers and awareness gaps rather than a lack of clinical utility.
Pharmacotherapy evidence supports the following hierarchy (Cochrane component network meta-analysis [NMA], 2023) (Table 1): nicotine e-cigarettes odds ratio (OR), 2.37 (95% credible interval [CrI], 1.73–3.24; high certainty), varenicline OR, 2.33 (95% CrI, 2.02–2.68; high), cytisinicline OR, 2.21 (95% CrI, 1.66–2.97; high certainty), and, crucially, combination NRT showed no significant difference from varenicline (OR, 1.06; 95% CrI, 0.75–1.48) [22,23]. The varenicline market underwent substantial disruption beginning in September 2021, when the global nitrosamine (N-nitroso-varenicline) impurity crisis led to voluntary recall and supply suspension of the Champix originator. Following approximately 3 years of market absence, Pfizer formally withdrew its Korean marketing authorization in August 2024. However, by late 2021, domestic generic varenicline products had become the main remaining formulations in Korea, and varenicline continued to be prescribed as a first-line agent [24]. Importantly, the absence of a clear difference versus varenicline (OR, 1.06; 95% CrI, 0.75–1.48) supports combination NRT as an evidence-based first-line option offering clinicians greater prescribing flexibility in Korean practice, particularly in the context of a contracting cessation-treatment infrastructure. Cytisinicline (PDUFA June 2026) has limited near-term relevance because of the regulatory timeline (Table 1) [25-27].
The network meta-analysis reported an RR of 1.86 (95% confidence interval [CI], 1.54–2.24) for personalized digital interventions [28]. Korea has established regulatory and health-insurance listing pathways for digital therapeutics [29,30].
For special populations, the EAGLES trial definitively established that varenicline, bupropion, and NRT do not increase neuropsychiatric adverse events in patients with psychiatric comorbidities [31], and a Cochrane review demonstrated that cessation improves anxiety, depression, and stress with effect sizes comparable to antidepressant therapy [32]. For pregnant women, financial incentives show particularly strong effects (Cochrane RR, approximately 2.38) [33]. These findings are critical for Korean clinicians, given the persistent undertreatment of smoking in prenatal care and the high prevalence of comorbid psychiatric conditions among Korean smokers.
The 2024 WHO guideline recommends varenicline, NRT and bupropion as first-line pharmacological options; combination NRT is an option for patients using NRT. Cytisine is also recommended, with its availability and regulatory status varying across countries [34]. However, the guideline’s application in the Korean context requires adaptation: the absence of cytisine from the Korean formulary and the ongoing contraction of cessation treatment infrastructure collectively limit the reach of evidence-based options available to Korean clinicians compared to their counterparts in the United Kingdom, Canada, or Australia.
Warn: pack warnings and labeling (FCTC Article 11)
Korea introduced pictorial health warnings in 2016. The fifth-cycle marking manual, applicable from December 23, 2024, specifies warnings occupying at least 50% of the front and back display areas, comprising a pictorial component of 30% and warning text of 20% [35]. The total warning area should be distinguished from the pictorial component when comparing coverage with FCTC Article 11 [36]. Korea has not implemented standardized packaging; the Cochrane review supports its potential role in tobacco control [37]. Expanding pictorial warnings and considering standardized packaging remain policy options.

Protect: novel product regulation (FCTC Articles 5.3 and 13)

Interpretation of the evidence on e-cigarettes for smoking cessation varies markedly across international guidelines: National Institute for Health and Care Excellence (UK) uniquely recommends e-cigarettes as a cessation tool; WHO explicitly excludes them; the U.S. Preventive Services Task Force rates the evidence as insufficient; and Canada conditionally recommends against their use [34,38-40]. This divergence reflects different value judgments about adult cessation benefits versus youth initiation risks rather than disagreement over the underlying evidence. The quality asymmetry in the evidence base—high-certainty adult RCT data versus observational youth studies—warrants explicit acknowledgment in policy deliberations (Table 3) [41,42].
For Korean clinicians, this divergence creates practical uncertainty. Korea currently maintains a precautionary stance aligned with WHO but lacks a formal national guideline position. A calibrated approach—strict prohibition of youth access coupled with clinical shared decision-making for treatment-refractory adult smokers, modeled on the UK’s tiered access framework—could be considered in future guideline development. Notably, Korea’s current regulatory posture presents a paradox: conservative policy and misinformation effectively deny adult smokers access to harm-reduction alternatives, while inadequate enforcement—including unrestricted online sales of liquid nicotine and unattended vending machines—facilitates youth nicotine initiation. A forward-looking policy recalibration that separates adult harm reduction from youth access prevention is needed [38].
Enforce and raise: legislative reform and price policy
The December 2025 Tobacco Business Act amendment, passed near-unanimously, expanded the definition of “tobacco” to include synthetic nicotine—the first definitional change in 37 years [43]. Implementation was scheduled for April 2026 to close the regulatory loophole for synthetic nicotine products. A news report citing a government estimate projected additional annual revenue of approximately ₩930 billion, including the National Health Promotion Levy [44]. The Tobacco Hazard Management Act entered into force on November 1, 2025 [45]. Relevant amendments to K-REACH, promulgated on February 6, 2024, entered into force on August 7, 2025, with specified provisions effective January 1, 2025 [46].
Korean cigarette prices remained at ₩4,500 from 2015 through the review’s evidence cutoff [4]. Korea’s prices rank fifth-lowest among the 38 OECD countries. The Korea Institute for Health and Social Affairs recommends a minimum price increase to ₩8,000–10,000 with automatic inflation indexation [47]. International evidence consistently demonstrates that price increases are the single most effective population-level tobacco control measure; the UK’s introduction of a vaping excise duty with commensurate tobacco duty increases to preserve price differentials offers an instructive policy model [48].
The analysis by the Korea Institute for Health and Social Affairs demonstrates that Korea’s current tobacco tax structure, in which the specific tax component has eroded in real terms over a decade, fails to achieve the WHO-recommended benchmark that taxes constitute at least 75% of the retail price [47]. International evidence indicates that a 10% increase in cigarette prices reduces consumption by approximately 4% in high-income countries, with larger effects among youth and lower-income populations [49,50].
Strategic priorities for Korean smoking cessation
This analysis identifies four strategic priorities for Korean tobacco control, organized by anticipated population-level impact (Figure 1).
The ordering of these four priorities was not derived from a de novo quantitative simulation model. Rather, the priorities were ranked using a semi-quantitative policy matrix incorporating five axes: (1) strength of intervention-effectiveness evidence, (2) expected population-level impact in the Korean context, (3) urgency in the current Korean regulatory landscape, (4) feasibility within the 2025–2026 legislative window, and (5) equity implications. Korea-specific simulation modeling (Levy et al. [51] in 2010) identified tobacco tax and price policies as the dominant driver of historical reductions in smoking prevalence, supporting the first priority. International evidence on price elasticity in high-income countries indicates that a 10% price increase reduces cigarette consumption by approximately 4% (International Agency for Research on Cancer Handbook Vol 14 [50]; Chaloupka et al. [49] in 2012). Cochrane systematic reviews on digital cessation (Whittaker et al. [52] in 2019; Taylor et al. [53] in 2017) provide evidence of moderate-to-low certainty supporting the integration of mobile and internet-based cessation services into national coverage. We did not perform new SimSmoke modeling for the 2025–2026 reform scenario; Korea-specific quantitative impact estimates of the proposed reforms therefore remain a research gap, as acknowledged in the Limitations section.
First, price and packaging policy reform represents the intervention with the greatest anticipated impact. The 10-year price freeze is the most significant modifiable barrier to further prevalence reduction. A minimum increase to ₩8,000–10,000 with inflation indexation, combined with the adoption of standardized packaging, warrants priority consideration as population-level measures with limited additional healthcare expenditure [37,47].
Second, evidence-based recalibration of novel product regulation is urgently needed. Korea’s approach to applying the full tobacco taxation regime to synthetic nicotine products, although it closes a regulatory gap, should be calibrated to preserve harm-reduction price differentials. The current situation is paradoxical: conservative regulation and misinformation deny adult smokers evidence-based harm-reduction options, while enforcement gaps—online liquid nicotine sales and unattended vending machines—facilitate youth initiation. Resolving this paradox requires Korea to develop an explicit national position through a tiered regulatory framework that separates adult harm reduction from youth access prevention [38].
Third, product-specific monitoring must be modernized. The widening cigarette-total gap (7.5 percentage points in males) calls for elevating total tobacco product use to a primary national indicator, with gender-specific surveillance and routine cotinine biomarker use to address documented self-report underestimation, particularly among women [5,18].
Fourth, pharmacotherapy optimization and digital integration should address immediate clinical gaps. Combination NRT (OR, 1.06 vs. varenicline) could be incorporated more explicitly into clinician education as a first-line option with a comparable effect estimate, thereby expanding prescribing flexibility, and reimbursement for digital cessation therapeutics (RR, 1.86) warrants policy consideration [22,23,28,29].
The December 2025 legislative reform creates a policy window. A news report citing a government estimate projected approximately ₩930 billion in additional annual revenue, including the National Health Promotion Levy [44]. Earmarking part of this revenue for tobacco control could provide a fiscal basis for expanded cessation services and efforts to reverse the 62% participation decline. International precedents support this fiscal mechanism: Thailand’s ThaiHealth Foundation, established in 2001 with a 2% surcharge on tobacco and alcohol taxes, has sustained national-scale health promotion programs (Adulyanon [54] in 2012); California Proposition 99 (1988) similarly demonstrated that an earmarked tobacco surcharge can fund multi-decade tobacco-control infrastructure [55].
Implementation of these four priorities would require coordinated action across multiple government agencies. The Ministry of Health and Welfare, Ministry of Economy and Finance, Korea Disease Control and Prevention Agency (KDCA), and the National Health Insurance Service each has jurisdiction over different elements of the tobacco control ecosystem. The WHO FCTC MPOWER framework can serve as both an analytical tool and a coordination framework: by mapping each intervention to a specific MPOWER domain, policymakers can identify which agency bears primary responsibility and where interagency coordination is most critical. Korea’s experience with the December 2025 legislative reform—which required alignment between the National Assembly, the Ministry of Health and Welfare, and the Ministry of Environment—demonstrates that such coordination is achievable when political will exists.
Methodological considerations
This review’s AI-assisted workflow supported literature scoping and the identification of discrepant claims, as described in the Methods. Two methodological considerations warrant discussion. First, specific clinical questions addressed in this narrative review could be reassessed in prospectively registered systematic reviews with prespecified eligibility criteria and dual-reviewer screening. Any AI use in those reviews should also be documented through prompt and output logging. Second, this review does not establish the comparative time efficiency or cost-effectiveness of AI-assisted synthesis. Future evaluations should account for both AI-assisted tasks and the human effort required for primary-source verification.
The practical value of multi-source corroboration is illustrated by specific instances in this review. For 2023 male smoking prevalence, Claude reported 32.4% while Gemini reported 31.8%; primary source verification (KDCA press release, December 3, 2024) confirmed 32.4%—a difference that, if undetected, would have understated a clinically significant rebound. For the Champix marketing authorization withdrawal date, ChatGPT cited June 2024 while Gemini cited August 2024; the official notice of the Ministry of Food and Drug Safety confirmed August 21, 2024. Of 23 such discrepancies identified among the four AI platforms, 18 (78%) were definitively resolved through primary source verification (Supplement 3). These examples demonstrate that no single AI model should be relied upon in isolation, and that systematic multi-source corroboration—functioning as a form of methodological triangulation—can detect errors that would otherwise propagate into the evidence synthesis.
Limitations
Several limitations should be acknowledged. First, this is a structured narrative review and does not employ the exhaustive duplicate screening or quantitative pooling characteristic of systematic reviews. Second, the MPOWER framework, while comprehensive, may not capture all dimensions of Korea’s tobacco control challenges, such as industry influence on policy or cultural factors in smoking behavior. Third, the rapidly evolving regulatory landscape means that some policy details may change between writing and publication. Fourth, the AI-assisted evidence synthesis approach introduces nondeterministic elements that limit strict reproducibility; our structured matrix approach captures content patterns rather than specific outputs. Fifth, each AI model reflects its training corpus, potentially overrepresenting English-language sources; Korean-language policy documents were independently verified against government originals. The topic-mapping matrix coding (Supplement 1) was performed by a single rater without independent duplicate assessment, a methodological limitation of this narrative review.
Sixth, the MPOWER framework organizes interventions by policy domain rather than by implementation feasibility or political economy. Some high-impact interventions (notably price increases) face disproportionate political resistance relative to their evidence base, a dynamic that the framework does not capture. Finally, this review focuses on the supply side of cessation services and does not systematically address demand-side factors such as smoking culture, social norms, or industry marketing strategies that influence cessation behavior.
An additional methodological limitation is that the verbatim AI prompts used during the v10.1 synthesis stage were not prospectively archived; accordingly, we report representative reconstructed prompts (Supplement 8) rather than claiming a complete prompt audit trail. Future AI-assisted review articles should prospectively log prompts, model versions, dates of use, raw responses, and verification steps to improve methodological reproducibility and research integrity and transparency.
We did not perform de novo simulation modeling (e.g., SimSmoke) for the 2025–2026 reform scenario. Korea-specific quantitative impact estimates—projected prevalence reduction, deaths averted, or cost-effectiveness for each strategic priority—remain a research gap. Future work should integrate updated Korea-specific calibration of established simulation frameworks with the post-2015 tax-freeze and HTP market data.
Korea’s smoking cessation landscape in 2026 presents critical gaps alongside unprecedented opportunities. The MPOWER framework analysis shows that the most impactful interventions—price increases and standardized packaging—remain unimplemented despite strong evidence, while cessation infrastructure has contracted despite demonstrated effectiveness. The December 2025 Tobacco Business Act amendment creates a legislative window to address these gaps comprehensively. Four strategic priorities—price and packaging reform, calibrated novel product regulation, modernized surveillance, and pharmacotherapy optimization with digital integration—provide an actionable roadmap for Korean tobacco control. The challenge is not a lack of evidence but a gap between evidence and implementation. A news report citing a government estimate projected approximately ₩930 billion in additional annual revenue, including the National Health Promotion Levy, from synthetic nicotine taxation [44]. If partly earmarked for tobacco control, this projected revenue could support action across all four priorities. Korea now has substantial evidence, legislative momentum, and a potential fiscal basis for meaningful tobacco control reform; the remaining challenge is to translate these conditions into sustained policy action.

Conflict of interest

SH Ahn serves as Chief Medical Officer of Mobile Doctor Inc. and Medical Algorithm Director of MoDoc AI Inc. Otherwise, no other potential conflict of interest relevant to this article was reported.

Acknowledgments

Large language models (Claude [Anthropic], ChatGPT [OpenAI], Gemini [Google], and Consensus [Consensus NLP]) were used as tools for literature retrieval and preliminary synthesis under the structured multi-source corroboration protocol described in the Methods section. All AI-generated outputs were verified against primary sources, and all final content decisions, clinical interpretations, and policy recommendations represent the authors’ expert judgment. No AI tool is listed as an author, consistent with ICMJE recommendations. Full methodological and AI-use transparency details are provided in Supplements 1–4, 8, 9, and 12.

Funding

None.

Author contribution

Conceptualization: SHA, YSC. Data curation: SHA. Formal analysis: SHA. Investigation: SHA. Methodology: SHA, YSC. Validation: SHA, YSC. Visualization: SHA. Project administration: YSC. Supervision: YSC. Writing–original draft: SHA. Writing–review & editing: YSC. Final approval of the manuscript: all authors.

Data of this research are available from the corresponding author upon reasonable request.
Supplementary materials can be found via https://doi.org/10.4082/kjfm.26.0104.
Supplement 1.
Topic-mapping matrix: AI source coverage by category.
kjfm-26-0104-Supplementary-1.pdf
Supplement 2.
AI source-specific contribution profiles.
kjfm-26-0104-Supplementary-2.pdf
Supplement 3.
Inter-source discrepancy identification and resolution log.
kjfm-26-0104-Supplementary-3.pdf
Supplement 4.
Three-stage AI multisource corroboration protocol summary.
kjfm-26-0104-Supplementary-4.pdf
Supplement 5.
Korean tobacco regulation legislative timeline (2024–2026).
kjfm-26-0104-Supplementary-5.pdf
Supplement 6.
Multi-source corroboration summary.
kjfm-26-0104-Supplementary-6.pdf
Supplement 7.
Methodological considerations for AI-assisted evidence synthesis.
kjfm-26-0104-Supplementary-7.pdf
Supplement 8.
Representative reconstructed AI prompts used for AIassisted multi-source evidence synthesis, organized by workflow category.
kjfm-26-0104-Supplementary-8.pdf
Supplement 9.
What the AI tools did not do.
kjfm-26-0104-Supplementary-9.pdf
Supplement 10.
SANRA application to this study.
kjfm-26-0104-Supplementary-10.pdf
Supplement 11.
Database search strategies for the v11 reproducible search reconstruction.
kjfm-26-0104-Supplementary-11.pdf
Supplement 12.
AI-use transparency matrix: tools, workflow roles, human verification, and documentation status.
kjfm-26-0104-Supplementary-12.pdf
Supplement 13.
Summary of key evidence supporting the four strategic priorities (policy-level outcomes; formal GRADE not applied).
kjfm-26-0104-Supplementary-13.pdf
Supplement 14.
Artificial intelligence (AI)-assisted multi-source evidence synthesis workflow used for this study (MPOWER framework analysis of Korean smoking cessation policy, 2021–2026).
kjfm-26-0104-Supplementary-14.pdf
Supplementary References
kjfm-26-0104-Supplementary-References.pdf
Figure. 1.
Strategic priorities for Korean smoking cessation: an MPOWER framework analysis. This figure illustrates four strategic priorities organized by anticipated population-level impact: (1) price and packaging policy reform, (2) evidence-based novel product regulation, (3) product-specific monitoring modernization, and (4) pharmacotherapy optimization and digital integration. Each priority is mapped to the relevant MPOWER domain(s) and supported by key findings from the evidence reviewed. FCTC, Framework Convention on Tobacco Control; OECD, Organization for Economic Cooperation and Development; WHO, World Health Organization; HTP, heated tobacco product; OR, odds ratio; VAR, varenicline; NRT, nicotine replacement therapy; RR, relative risk; RCTs, randomized controlled trials; NHIS, National Health Insurance Service.
kjfm-26-0104f1.jpg
Table 1.
Comparative efficacy of cessation pharmacotherapies (Cochrane NMA 2023)
Intervention Key effect estimate (95% CrI) Certainty Key characteristics
Nicotine e-cigarettes 2.37 (1.73–3.24) High Highest point estimate; guideline divergence
Varenicline 2.33 (2.02–2.68) High Standard first-line; originator withdrawn; generics available [24]
Cytisinicline 2.21 (1.66–2.97) High Not yet available in Korea; limited near-term relevance given regulatory timeline [25-27]
Combination NRT OR 1.06 vs. VAR (0.75–1.48) High No clear difference vs. VAR; expands prescribing flexibility in the current Korean context
Bupropion 1.43 (1.26–1.62) High Oral alternative; seizure threshold risk

Effect estimates are adapted from the Cochrane component NMA by Lindson et al. [22] in 2023. The combination-NRT estimate versus varenicline (OR, 1.06; 95% CrI, 0.75–1.48) is from Cahill et al. [23] in 2013 and uses varenicline rather than placebo as the comparator.

NMA, network meta-analysis; CrI, credible interval; OR, odds ratio; VAR, varenicline; NRT, nicotine replacement therapy.

Table 2.
Adult smoking prevalence trends (KNHANES 2022–2024)
Indicator Year
Trend
2022 2023 2024 (Preliminary)a)
Male cigarette (%) 30.0 32.4 28.5 Fluctuating (within sampling variability)
Female cigarette (%) 5.0 6.3 4.2 Fluctuating (within sampling variability)
Male total tobacco (%) - 38.9 36.0 -
Female total tobacco (%) - 8.3 6.9 -
Cigarette-total gap (male) (%p) - 6.5 7.5 Widening
Cigarette-total gap (female) (%p) - 2.0 2.7 Widening

From Korea Disease Control and Prevention Agency. KNHANES 2023 results. Korea Disease Control and Prevention Agency; 2024 [17].

KNHANES, Korea National Health and Nutrition Examination Survey.

a)2024 figures are preliminary [5].

Table 3.
International guideline positions on key cessation topics (2024–2025)
Topic WHO 2024 [34] NICE NG209 [38] USPSTF [39] Korea (practice) Canada TF 2025 [40]
Brief advice Strong recommendation Recommended Grade A 5A/5R adopted Recommended
Varenicline 1st-line 1st-line Strong recommendation 1st-line preferred Recommended
Cytisine Recommended Listed Not included Not listed Strong recommendation
E-cigarettes Excluded Recommended Insufficient (I) Not endorsed Conditional against
Plain packaging Recommended Implemented - Not implemented Implemented

The Korea column summarizes current policy and clinical practice rather than a formal national guideline position.

WHO, World Health Organization; NICE, National Institute for Health and Care Excellence; NG209, NICE Guideline 209; USPSTF, U.S. Preventive Services Task Force; TF, Task Force; 5A, ask, advise, assess, assist, arrange; 5R, relevance, risks, rewards, roadblocks, repetition.

  • 1. Korea Disease Control and Prevention Agency. Smoking-attributable mortality and disease burden study. Korea Disease Control and Prevention Agency; 2024.
  • 2. Korea Disease Control and Prevention Agency. Socioeconomic costs of smoking study. Korea Disease Control and Prevention Agency; 2024.
  • 3. National Health Insurance Service. Cessation program statistics; KDCA cessation service utilization data. National Health Insurance Service; 2024.
  • 4. Ministry of Economy and Finance. Tobacco market trends in 2024 [Internet]. Ministry of Economy and Finance 2025 [cited 2026 Sep 10]. Available from: https://mofe.go.kr/nw/nes/detailNesDtaView.do?menuNo=4010100&searchNttId1=MOSF_000000000073584
  • 5. Korea Disease Control and Prevention Agency. KNHANES 2024 preliminary results. Korea Disease Control and Prevention Agency; 2025.
  • 6. Korea Disease Control and Prevention Agency. 20th Youth Health Behavior Survey and Youth Health Panel Survey detailed analysis. Korea Disease Control and Prevention Agency; 2024.
  • 7. World Health Organization. MPOWER: a policy package to reverse the tobacco epidemic. World Health Organization; 2008.
  • 8. Thirunavukarasu AJ, Ting DS, Elangovan K, Gutierrez L, Tan TF, Ting DS. Large language models in medicine. Nat Med 2023;29:1930-40.
  • 9. Ji Z, Lee N, Frieske R, Yu T, Su D, Xu Y, et al. Survey of hallucination in natural language generation. ACM Comput Surv 2023;55:1-38.
  • 10. Sallam M. ChatGPT utility in healthcare education, research, and practice: systematic review on the promising perspectives and valid concerns. Healthcare (Basel) 2023;11:887.
  • 11. Athaluri SA, Manthena SV, Kesapragada VS, Yarlagadda V, Dave T, Duddumpudi RT. Exploring the boundaries of reality: investigating the phenomenon of artificial intelligence hallucination in scientific writing through ChatGPT references. Cureus 2023;15:e37432.
  • 12. Alshami A, Elsayed M, Ali E, Eltoukhy AE, Zayed T. Harnessing the power of ChatGPT for automating systematic review process: methodology, case study, limitations, and future directions. Systems (Basel) 2023;11:351.
  • 13. Borah R, Brown AW, Capers PL, Kaiser KA. Analysis of the time and workers needed to conduct systematic reviews of medical interventions using data from the PROSPERO registry. BMJ Open 2017;7:e012545.
  • 14. Baethge C, Goldbeck-Wood S, Mertens S. SANRA: a scale for the quality assessment of narrative review articles. Res Integr Peer Rev 2019;4:5.
  • 15. Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. J Med Libr Assoc 2021;109:174-200.
  • 16. International Committee of Medical Journal Editors. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. International Committee of Medical Journal Editors; 2024.
  • 17. Korea Disease Control and Prevention Agency. KNHANES 2023 results. Korea Disease Control and Prevention Agency; 2024.
  • 18. Jung-Choi KH, Khang YH, Cho HJ. Hidden female smokers in Asia: a comparison of self-reported with cotinine-verified smoking prevalence rates in representative national data from an Asian population. Tob Control 2012;21:536-42.
  • 19. Oh SW. Haman-gun smoking cessation clinic records a 37.6% six-month smoking cessation success rate. Asia Today [Internet]. 2026 Jan 5 [cited 2026 Sep 10]. Available from: https://www.asiatoday.co.kr/kn/view.php?key=20260105010001404
  • 20. Ministry of Health and Welfare. Regional cessation support centers: operational performance and outreach services for underserved populations. Ministry of Health and Welfare; 2024.
  • 21. National Health Insurance Service. National Cessation Treatment Support Program annual statistics. National Health Insurance Service; 2024.
  • 22. Lindson N, Theodoulou A, Ordonez-Mena JM, Fanshawe TR, Sutton AJ, Livingstone-Banks J, et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. Cochrane Database Syst Rev 2023;9:CD015226.
  • 23. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013;2013:CD009329.
  • 24. Ministry of Food and Drug Safety. Champix supply suspension notice (June 2021); marketing authorization voluntary withdrawal (August 21, 2024). Ministry of Food and Drug Safety; 2024.
  • 25. Rigotti NA, Benowitz NL, Prochaska J, Leischow S, Nides M, Blumenstein B, et al. Cytisinicline for smoking cessation: a randomized clinical trial. JAMA 2023;330:152-60.
  • 26. Rigotti NA, Benowitz NL, Prochaska JJ, Rubinstein M, Clarke A, Blumenstein B, et al. Cytisinicline for smoking cessation: the ORCA phase 3 replication randomized clinical trial. JAMA Intern Med 2025;185:648-55.
  • 27. Achieve Life Sciences. Achieve Life Sciences announces FDA acceptance of cytisinicline new drug application for treatment of nicotine dependence for smoking cessation. Achieve Life Sciences; 2025.
  • 28. Li S, Li Y, Xu C, Tao S, Sun H, Yang J, et al. Efficacy of digital interventions for smoking cessation by type and method: a systematic review and network meta-analysis. Nat Hum Behav 2025;9:2054-65.
  • 29. Ministry of Food and Drug Safety. Guideline for approval and review of digital therapeutics devices (Guidance No. 1045-01) [Internet]. Ministry of Food and Drug Safety 2020 [cited 2026 Sep 10]. Available from: https://www.mfds.go.kr/brd/m_1060/view.do?seq=14596
  • 30. Health Insurance Review and Assessment Service. Notice of revised operating guidelines for temporary health-insurance listing of innovative medical technologies (digital therapeutics and artificial intelligence) [Internet]. Health Insurance Review and Assessment Service 2024 [cited 2026 Sep 10]. Available from: https://www.hira.or.kr/bbsDummy.do?brdBltNo=11216&brdScnBltNo=4&pgmid=HIRAA020002000100
  • 31. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomized, placebo-controlled clinical trial. Lancet 2016;387:2507-20.
  • 32. Taylor GM, Lindson N, Farley A, Leinberger-Jabari A, Sawyer K, Te Water Naude R, et al. Smoking cessation for improving mental health. Cochrane Database Syst Rev 2021;3:CD013522.
  • 33. Notley C, Gentry S, Livingstone-Banks J, Bauld L, Perera R, Hartmann-Boyce J. Incentives for smoking cessation. Cochrane Database Syst Rev 2019;7:CD004307.
  • 34. World Health Organization. Clinical treatment guideline for tobacco cessation in adults. World Health Organization; 2024.
  • 35. Korea Health Promotion Institute. Fifth-cycle tobacco packaging health-warning marking manual [Internet]. Korea Health Promotion Institute [cited 2026 Sep 10]. Available from: https://nosmk.khepi.or.kr/nsk/user/extra/ntcc/nosmokeFile/fileView/jsp/Page.do?fileNo=803&siteMenuIdx=130
  • 36. World Health Organization. WHO Framework Convention on Tobacco Control: Articles 11 and 20 [Internet]. World Health Organization 2003;[cited 2026 Sep 10]. Available from: https://fctc.who.int/convention/9241591013
  • 37. McNeill A, Gravely S, Hitchman SC, Bauld L, Hammond D, Hartmann-Boyce J. Tobacco packaging design for reducing tobacco use. Cochrane Database Syst Rev 2017;4:CD011244.
  • 38. National Institute for Health and Care Excellence. NG209 Tobacco: preventing uptake, promoting quitting and treating dependence. National Institute for Health and Care Excellence; 2025.
  • 39. US Preventive Services Task Force; Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, et al. Interventions for tobacco smoking cessation in adults, including pregnant persons: US preventive services task force recommendation statement. JAMA 2021;325:265-79.
  • 40. Thombs BD, Traversy G, Reynolds DL, Lang E, Groulx S, Wilson BJ, et al. Recommendations on interventions for tobacco smoking cessation in adults in Canada. CMAJ 2025;197:E846-61.
  • 41. Hartmann-Boyce J, McRobbie H, Lindson N, Bullen C, Begh R, Theodoulou A, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2020;10:CD010216.
  • 42. Wills TA, Soneji SS, Choi K, Jaspers I, Tam EK. E-cigarette use and respiratory disorders: an integrative review of converging evidence from epidemiological and laboratory studies. Eur Respir J 2021;57:1901815.
  • 43. Tobacco Business Act Amendment, Law No. 21216 (Dec 23, 2025).
  • 44. Jeong SR. 98% of synthetic nicotine is from China… imports increase eightfold as regulation stalls. The Korea Economic Daily [Internet]. 2025 Sep 9 [cited 2026 Sep 10]. Available from: https://www.hankyung.com/article/2025090932051
  • 45. Tobacco Hazard Management Act, Act No. 19815 (Oct 31, 2023), effective Nov 1, 2025 [Internet]. Korean Law Information Center 2025 [cited 2026 Sep 10]. Available from: https://law.go.kr/LSW/lsInfoP.do?lsiSeq=255879
  • 46. Amendment to the Act on the Registration and Evaluation of Chemicals, Act No. 20232 (Feb 6, 2024) [Internet]. Korean Law Information Center 2025 [cited 2026 Sep 10]. Available from: https://law.go.kr/LSW/lsInfoP.do?lsiSeq=259879&viewCls=lsRvsDocInfoR
  • 47. Korea Institute for Health and Social Affairs. Tobacco price policy effectiveness analysis. Korea Institute for Health and Social Affairs; 2024.
  • 48. HM Revenue & Customs. Introduction of vaping products duty from 1 October 2026 [Internet]. HM Revenue & Customs 2025 [cited 2026 Sep 10]. Available from: https://www.gov.uk/government/publications/introduction-of-vaping-products-duty-from-1-october-2026
  • 49. Chaloupka FJ, Yurekli A, Fong GT. Tobacco taxes as a tobacco control strategy. Tob Control 2012;21:172-80.
  • 50. International Agency for Research on Cancer. Effectiveness of tax and price policies for tobacco control: IARC Handbooks of Cancer Prevention Volume 14 [Internet]. IARC 2011 [cited 2026 Sep 10]. Available from: https://publications.iarc.who.int/Book-And-Report-Series/Iarc-Handbooks-Of-Cancer-Prevention/Effectiveness-Of-Tax-And-Price-Policies-For-Tobacco-Control-2011
  • 51. Levy DT, Cho SI, Kim YM, Park S, Suh MK, Kam S. SimSmoke model evaluation of the effect of tobacco control policies in Korea: the unknown success story. Am J Public Health 2010;100:1267-73.
  • 52. Whittaker R, McRobbie H, Bullen C, Rodgers A, Gu Y, Dobson R. Mobile phone text messaging and app-based interventions for smoking cessation. Cochrane Database Syst Rev 2019;10:CD006611.
  • 53. Taylor GM, Dalili MN, Semwal M, Civljak M, Sheikh A, Car J. Internet-based interventions for smoking cessation. Cochrane Database Syst Rev 2017;9:CD007078.
  • 54. Adulyanon S. Funding health promotion and disease prevention programmes: an innovative financing experience from Thailand. WHO South East Asia J Public Health 2012;1:201-7.
  • 55. California Department of Public Health. Legislative mandate for tobacco control: Proposition 99 [Internet]. California Department of Public Health 2017 [cited 2026 Sep 10]. Available from: https://www.cdph.ca.gov/Programs/CCDPHP/DCDIC/CTCB/Pages/LegislativeMandateforTobaccoControlProposition99-.aspx

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      Download Citation

      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:

      Include:

      Smoking cessation policy gaps in South Korea: an MPOWER Framework analysis with AI-assisted multi-source evidence synthesis (2021–2026)
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Smoking cessation policy gaps in South Korea: an MPOWER Framework analysis with AI-assisted multi-source evidence synthesis (2021–2026)
      Close

      Figure

      • 0
      Smoking cessation policy gaps in South Korea: an MPOWER Framework analysis with AI-assisted multi-source evidence synthesis (2021–2026)
      Image
      Figure. 1. Strategic priorities for Korean smoking cessation: an MPOWER framework analysis. This figure illustrates four strategic priorities organized by anticipated population-level impact: (1) price and packaging policy reform, (2) evidence-based novel product regulation, (3) product-specific monitoring modernization, and (4) pharmacotherapy optimization and digital integration. Each priority is mapped to the relevant MPOWER domain(s) and supported by key findings from the evidence reviewed. FCTC, Framework Convention on Tobacco Control; OECD, Organization for Economic Cooperation and Development; WHO, World Health Organization; HTP, heated tobacco product; OR, odds ratio; VAR, varenicline; NRT, nicotine replacement therapy; RR, relative risk; RCTs, randomized controlled trials; NHIS, National Health Insurance Service.
      Smoking cessation policy gaps in South Korea: an MPOWER Framework analysis with AI-assisted multi-source evidence synthesis (2021–2026)
      Intervention Key effect estimate (95% CrI) Certainty Key characteristics
      Nicotine e-cigarettes 2.37 (1.73–3.24) High Highest point estimate; guideline divergence
      Varenicline 2.33 (2.02–2.68) High Standard first-line; originator withdrawn; generics available [24]
      Cytisinicline 2.21 (1.66–2.97) High Not yet available in Korea; limited near-term relevance given regulatory timeline [25-27]
      Combination NRT OR 1.06 vs. VAR (0.75–1.48) High No clear difference vs. VAR; expands prescribing flexibility in the current Korean context
      Bupropion 1.43 (1.26–1.62) High Oral alternative; seizure threshold risk
      Indicator Year
      Trend
      2022 2023 2024 (Preliminary)a)
      Male cigarette (%) 30.0 32.4 28.5 Fluctuating (within sampling variability)
      Female cigarette (%) 5.0 6.3 4.2 Fluctuating (within sampling variability)
      Male total tobacco (%) - 38.9 36.0 -
      Female total tobacco (%) - 8.3 6.9 -
      Cigarette-total gap (male) (%p) - 6.5 7.5 Widening
      Cigarette-total gap (female) (%p) - 2.0 2.7 Widening
      Topic WHO 2024 [34] NICE NG209 [38] USPSTF [39] Korea (practice) Canada TF 2025 [40]
      Brief advice Strong recommendation Recommended Grade A 5A/5R adopted Recommended
      Varenicline 1st-line 1st-line Strong recommendation 1st-line preferred Recommended
      Cytisine Recommended Listed Not included Not listed Strong recommendation
      E-cigarettes Excluded Recommended Insufficient (I) Not endorsed Conditional against
      Plain packaging Recommended Implemented - Not implemented Implemented
      Table 1. Comparative efficacy of cessation pharmacotherapies (Cochrane NMA 2023)

      Effect estimates are adapted from the Cochrane component NMA by Lindson et al. [22] in 2023. The combination-NRT estimate versus varenicline (OR, 1.06; 95% CrI, 0.75–1.48) is from Cahill et al. [23] in 2013 and uses varenicline rather than placebo as the comparator.

      NMA, network meta-analysis; CrI, credible interval; OR, odds ratio; VAR, varenicline; NRT, nicotine replacement therapy.

      Table 2. Adult smoking prevalence trends (KNHANES 2022–2024)

      From Korea Disease Control and Prevention Agency. KNHANES 2023 results. Korea Disease Control and Prevention Agency; 2024 [17].

      KNHANES, Korea National Health and Nutrition Examination Survey.

      2024 figures are preliminary [5].

      Table 3. International guideline positions on key cessation topics (2024–2025)

      The Korea column summarizes current policy and clinical practice rather than a formal national guideline position.

      WHO, World Health Organization; NICE, National Institute for Health and Care Excellence; NG209, NICE Guideline 209; USPSTF, U.S. Preventive Services Task Force; TF, Task Force; 5A, ask, advise, assess, assist, arrange; 5R, relevance, risks, rewards, roadblocks, repetition.

      TOP